| Abstrakt: |
A recent report from Harvard Medical School discusses research on ovarian cancer and the potential resistance to bispecific T-cell engager (BiTE) therapy. The study focused on the role of hypoxia in the modulation of MUC16, a protein associated with ovarian cancer, and its impact on resistance to BiTE therapy. The researchers found that hypoxia led to a decrease in MUC16 expression on tumor cells, as well as changes in epithelial-mesenchymal transition (EMT) markers and the upregulation of epidermal growth factor receptor (EGFR). Understanding these mechanisms could provide valuable insights into BiTE therapy resistance in ovarian cancer. [Extracted from the article] |
